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Severe aplastic anemia (SAA) is a rare disorder leading to bone marrow failure, which if left untreated, is invariably
fatal. Conventional therapies with immunosuppressive therapy or allogeneic hematopoietic stem cell
transplantation (HSCT) are highly effective. HSCT can offer a greater outcome in younger patients who have
an available HLA match-related donor. Recent studies showing the addition of antithymocyte globulin
(ATG) to the conditioning regimen improves engraftment and reduces the risk of graft-versus-host disease
(GVHD).There are currently two ATG preparations in the USA, equine (or horse) and rabbit ATG. These
agents are pharmacologically distinct, having significant differences in their pharmacokinetics and in vivo
immunosuppressive effects [N Engl J Med 365(5):430–438, 2011]. Here, we report a case of two monozygotic
twins with constitutional SAA that evolved to myelodysplastic syndrome (MDS) who both underwent allogeneic
peripheral blood stem cell transplantation (PBSC) from the same single HLA antigen mismatched sibling donor with
the only difference in the transplant regimen being the type of ATG used in the preparative regimen; one twin received
horse ATG and the other received rabbit ATG during conditioning. This report emphasizes that dramatic differences in
donor T cell chimerism and clinical outcomes including GVHD can occur as a consequence of the type of ATG that is
utilized in the transplant conditioning regimen. These differences highlight that these agents should not be considered
interchangeable drugs when used in this setting.
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twinsBackground
Severe aplastic anemia (SAA) is a rare disorder leading
to bone marrow failure which, if left untreated, is invari-
ably fatal. Annually, 300 to 600 new cases of SAA are
diagnosed in the United States of America [1]. Conven-
tional therapies are highly effective and involve either
immunosuppressive therapy with horse antithymocyte
globulin (ATG) and cyclosporine (CSA) or allogeneic
hematopoietic stem cell transplantation (HSCT), with
the latter treatment offering superior outcome in youn-
ger individuals who have an available human leukocyte* Correspondence: uyenphuong18@yahoo.com
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vances in the procedure have been made over the past
three decades that have improved the survival of SAA
patients undergoing transplantation. Recent studies have
shown that chronic graft-versus-host disease (cGVHD)
is reduced when bone marrow as opposed to peripheral
blood stem cell transplantation (PBSC) is used as a graft
source for SAA. Nevertheless, graft rejection continues
to complicate this approach and remains a major con-
tributor to transplant-related mortality. Transplantation
of PBSC mobilized from donors using granulocyte-
colony stimulating factor (G-CSF) can also be used to
cure patients with ATG-refractory SAA and may be
associated with a reduced risk of graft rejection, particu-
larly in heavily transfused patients who are at high riskdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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phosphamide has been used to condition SAA patients
undergoing transplantation, with recent studies showing
that the addition of ATG to the conditioning regimen
improves engraftment and reduces the risk of graft-
versus-host disease (GVHD). ATG improves engraft-
ment by killing recipient lymphocytes that mediate graft
rejection and may also remain in the circulation at the
time of the transplant, killing alloreactive donor T cells
that mediate GVHD [2–10]. Equine or horse ATG
(Atgam) and rabbit ATG (thymoglobulin) are two
antithymocyte globulin preparations that are available in
the United States of America, for clinical use as im-
munosuppressive agents. Both drugs have been used in
off-label applications as conditioning agents for allogen-
eic HSCT for a variety of disorders including SAA. How-
ever, these agents are pharmacologically distinct, having
significant differences in their pharmacokinetics and
in vivo immunosupressive effects. A recent randomized
trial comparing these two agents as upfront therapy for
SAA outside of the context of a transplant showed the
depth and duration of CD3 T cell lymphopenia was
greater with rabbit ATG compared to equine ATG.
These differences, as well as the observation that re-
sponses in SAA were greater with equine ATG com-
pared to rabbit ATG, highlight that these agents should
not be considered interchangeable drugs when used in
this setting [2].
Case report
Twin #1 and twin #2 are two Vietnamese female mono-
zygotic twins who were born prematurely at 8 months of
gestation with a birth weight of approximately 1.8 kg
each. They were both diagnosed with SAA at 2 years of
age when they presented with symptoms related to pan-
cytopenia. Their initial treatment in Vietnam consisted
of corticosteroids and RBC and platelet transfusion sup-
port. In October 2001, at the age 8, both twins were
referred to the NHLBI in the United States of America,
for further evaluation and management.
Twin #1 was the first of the two identical twins to be
diagnosed with SAA and the first to develop myelodys-
plastic syndrome (MDS). A bone marrow biopsy in Oc-
tober 2001 showed 5–50 % cellularity without evidence
of dysplasia or blasts but with trisomy 8 being present in
35 % of metaphases consistent SAA evolution to MDS.
Testing for Fanconi’s anemia and paroxysmal nocturnal
hemoglobinuria (PNH) were negative. Peripheral blood
counts demonstrated an absolute neutrophil count
(ANC) of 417 cells/μl, a platelet count of 16 k/μl,
hemoglobin of 10 g/dl, and an absolute reticulocyte
count of 61 k/μl. She failed a trial of danazol therapy
and in April 2002, commenced treatment with horse
ATG 40 mg/kg/day for 4 days combined with CSA. Herpost-immunosuppression course was complicated by
multiple episodes of infection including non-specific
ileitis, colitis, bronchitis, pharyngitis, pneumonia, and an
ulcerative labial infection. There was no response at
6 months to horse ATG and she remained transfusion
dependent. In November 2002 at age 9, she underwent
an allogeneic PBSC transplant from her 9/10 HLA
match-related brother (donor and patient mismatched
at a single HLA A loci and fully matched at HLA at
the HLA B, C, DR, and DQ loci) after conditioning
with fludarabine 25 mg/m2 × 5 days, cyclophospha-
mide 60 mg/kg × 2 days, and rabbit ATG 3.5 mg/kg/
day × 4 days. CSA and MTX were used as GVHD
prophylaxis. She had neutrophil recovery on day +15
and platelet recovery on day +9. Her post-transplant
course was complicated by CMV reactivation which
responded to antiviral therapy and bacterial sepsis
which resolved with IV antibiotics. Lineage-specific
chimerism studies conducted on multiple occasions
from the time of engraftment until day +100 revealed
extremely low levels of donor T cell engraftment.
After day 100, she was observed to have a rapid de-
cline in her absolute reticulocyte count, which in the
context of very low levels of donor T cell chimerism,
led to concerns of impending graft rejection. There-
fore, on transplant day +113, she received an intra-
venous infusion of G-CSF-mobilized PBSCs from her
original stem cell donor containing 2 × 106 CD34+
cells/kg and 1.4 × 108 CD3+/kg cells. She eventually
converted 100 % donor T cell and myeloid chimerism
by transplant day +352 (Fig. 1a). She never developed
acute GVHD but did develop limited mouth and skin
chronic GVHD on day +175. By 6 years post-
transplant, her mild oral GVHD had completely re-
solved and all immunosuppressive medications were
discontinued.
Twin #2 was the second twin diagnosed with aplas-
tic anemia. On presentation to the NHLBI in 2002,
she had an ANC of 2100 cells/μl, a platelet count of
45 k/μl, a hemoglobin of 13.7 g/dl, and an absolute
reticulocyte count of 80.7 k/μl. Her bone marrow bi-
opsy demonstrated hypocellular marrow with less
than 5 % cellularity with a marked decrease in mega-
karyocytes. At that time, chromosome analysis by
metaphase banding of the peripheral blood and skin
fibroblasts revealed no evidence of trisomy 8 or any
other chromosome abnormality. Testing for Fanconi’s
anemia and PNH was negative. Similar to her sister,
she failed a 3-month trial of danazol treatment. Two
years later, in January 2003, she had a decline in her
blood counts: her ANC declined to 996/μl, platelets
to 15 k/μl, and hemoglobin to 9.4 g/dl, with an abso-
lute reticulocyte count of 74.2 k/μl. A repeat bone


















































Fig. 1 a Twin #1 chimerism timeline. b Twin #2 chimerism timeline
Vo et al. Journal of Hematology & Oncology  (2015) 8:78 Page 3 of 8cellularity with trisomy 8 now being detectable in
13 % of metaphases consistent with evolution to
MDS. In April 2004 at the age 11, she underwent an
allogeneic PBSC transplant from her 9/10 HLA
match-related brother who had donated PBSCs for
her syngeneic twin who had been transplanted
1.5 years earlier (similar to twin #1, the donor and
twin #2 were mismatched at a single HLA A loci and
fully matched at HLA at the HLA B, C, DR, and
DQ loci). Of note, both twins received similar trans-
planted allograft doses of CD34+ cells/kg and T cells/
kg (Table 1). Twin #2’s transplant conditioning regi-
men was virtually identical to her twin sister except
horse ATG (40 mg/kg/day × 4 days) rather than rabbitATG was utilized, given concerns that the latter drug
may have contributed to her twin sister’s poor donor
T cell engraftment. She had sustained donor engraft-
ment with neutrophil recovery occurring on day +12.
In contrast to her sister, she achieved very rapid
donor T cell engraftment, demonstrating 100 % donor
T cell chimerism by day +30 (Fig. 1b). Her post-
transplant course was complicated by grade II acute
GVHD involving her gut which responded to cortico-
steroid treatment. At 6 months post-transplant, she
developed extensive chronic GVHD of the skin with a
lichenoid rash on her face, trunk, and extremities that
improved partially following treatment with rituximab.
At 9 months post-transplant, she also developed
Table 1 Comparison of clinical data
Clinical data Twin #1 Twin #2
Disease progression
Age of presentation 2 2
Age at transplantation (years) 9 11
Sex Female Female
Diagnosis Constitutional SAA with trisomy 8 Constitutional SAA with trisomy 8
Karyotype at transplant Trisomy 8 Trisomy 8
Pre-transplantation characteristics
Absolute neutrophil count (k/μl) 417 996
Absolute reticulocyte count(k/μl) 61 71.2
Platelets (k/μl) 16 15
Time from diagnose to PBSC (years) 7 years 9 years
Recipient blood type AB+ AB+
Donor relationship Brother Brother
Donor blood type A+ A+
Donor sex Male Male
HLA match 9 out of 10 9 out of 10
RIC allogeneic PBSC
Age at transplant 9 11
Recipient blood type AB+ AB+
CD34+ cell dose (×106/kg) 6.24 × 10.6 6.32 × 10.6
CD3+ cell dose (×107/kg) 42.3 × 10.7 35.2 × 10.7
Day of 100 % donor T cell chimerism Day +352 Day +30
Received DLI and stem cell boost Yes No
Prophylaxis against GVHD MTX 5 mg/m2 day +1, +3, +6 MTX 5 mg/m2 day +1,+3, +6
Cyclosporine Cyclosporine
Conditioning regimen comparison
Cyclophosphamide 60 mg/kg IV × 2 Yes Yes
Fludarabine 25 mg/m2 IVBP × 5 Yes Yes
Rabbit ATG 3.5 mg/kg IV × 4 Yes No
Horse ATG 40 mg/kg IV × 4 No Yes
GVHD prophylaxis
MTX 5 mg/m2 × 3 Yes Yes
Cyclosporine Yes Yes
Post-transplantation GVHD
Time from HSCT to GVHD (months) 20 months <1 month
Acute GVHD No Yes (grade II GI tract)
Site of cGVHD Skin, mouth Skin, ocular, and lung
cGVHD grade (severity) Limited Extensive
cGVHD treatment Daclizumab, cyclosporine Cyclosporine, sirolimus, MMF, steroid
Daclizumab, rituximab, tacrolimus
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costeroids and placement of silicone punctal plugs. At
13 months post-transplant, she was diagnosed with
BOS which was treated with systemic and inhaledcorticosteroids and later with inhaled cyclosporine
solution [11]. Although her cGVHD symptoms improved
over time, she is now 10+ years post-transplant and,
in contrast to her identical twin sister, continues
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MMF, and tacrolimus to treat her chronic skin GVHD
(Fig. 3a–d).
Discussion
Both immunosuppressive therapy and allogeneic hema-
topoietic stem cell transplantation represent effective
therapy for patients with SAA [9, 10, 12, 13]. Graft rejec-
tion and GVHD, both which are critically influenced by
the composition of the allograft and the agents used in
the preparative regimen, remain obstacles to the success
of stem cell transplantation. Although donor T cells are
the main mediators of acute GVHD, their engraftment is
critical to prevent graft rejection and to restore protect-
ive host immunity post-transplant. Research continues
to determine the optimal conditioning regimen that pro-
motes donor engraftment while avoiding GVHD. Previ-
ously, we have shown that a transplant regimen utilizing
cyclophosphamide, fludarabine, and equine ATG condi-
tioning with a G-CSF-mobilized PBSC transplant results
in excellent engraftment and survival in heavily trans-
fused SAA patients who have failed prior immunosup-
pressive therapy. However, this regimen often results in
very rapid donor T cell engraftment, which was recently
shown to be an independent variable in a multivariate
analysis increasing the risk of chronic GVHD [14].
Here, we report data where syngeneic twins with
MDS who underwent allogeneic transplantation from
the same donor had dramatically different donor T cell
engraftment profiles and transplant outcome as a conse-
quence of using rabbit versus horse ATG in the prepara-
tive regimen (Fig. 2). Twin #1, who received rabbit
ATG with her conditioning, had a post-transplant




















Twin #2 – Hor
Fig. 2 Comparison of T cell chimerism between twinsdegrees of donor T cell engraftment and a declining
reticulocyte count necessitating a subsequent infusion
of donor PBSCs and T cells to avoid graft rejection.
Remarkably, this patient did not achieve full donor T cell
chimerism until day +352, never developed acute
GVHD, and only experienced mild chronic oral GVHD
which occurred after the PBSC boost. In contrast, twin
#2 who received from the same donor virtually the iden-
tical number of transplanted donor CD34+ cells and
a slightly lower number of transplanted CD3+ T cells,
received horse ATG with the conditioning regimen and
experienced very rapid and complete donor T cell chi-
merism which was associated with both acute GVHD
and extensive chronic GVHD (Fig. 3a–d). Of note, twin
#1 but not twin #2 had received ATG previously before
the transplant, and the donor and twin #2 were 2 years
older when the transplant was performed on twin #2
relative to twin #1. Therefore, we are unable to conclude
with complete certainty that the differences in clinical
outcomes were solely related to the use of rabbit versus
horse ATG in the conditioning regime. However, it is
important to note that because twin #1 but not twin #2
had received ATG previously before the transplant as
treatment for her aplastic anemia, she would have been
expected to be the more immunosuppressed twin pre-
transplant. This makes the chimerism differences more
likely attributable to the type of ATG utilized during
conditioning, as one would have expected to the more
immunosuppressed twin to have faster donor T cell en-
graftment, which was not the case with twin #1. We
theorize that the differences in the half-life of ATG likely
accounted for the dramatic differences in the speed of
donor T cell engraftment and the occurrence of and se-
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Fig. 3 a, b Twin #2 (left) 5 years and 3 months post-transplant and twin #1 (right) 6 years and 8 months post-transplant. c, d Twin #2 (left)
10 years and 6 months post-transplant and twin #1 (right) 11 years and 11 months post-transplant
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to horse ATG (5.7 days) [15, 16]. As a consequence,
rabbit ATG likely depleted transplanted donor T cells
in vivo much more efficiently in twin #1 compared to
twin #2 (who received horse ATG), which prevented
acute GVHD but also dramatically delayed donor T cell
engraftment, placing the patient at increased risk for
graft rejection. Given its shorter half-life, horse ATG
given to twin #2 was less effective in inducing in vivo Tcell depletion of transplanted donor cells, which resulted
in very rapid donor T cell engraftment with subsequent
acute and chronic GVHD. A recent retrospective, non-
randomized study comparing horse to rabbit ATG
in addition to cyclophosphamide as conditioning for
allogeneic HSCT patients with SAA reported similar ob-
servations, namely conditioning with rabbit ATG was
more protective against acute and chronic GVHD than
conditioning with horse ATG, with rabbit ATG being
Vo et al. Journal of Hematology & Oncology  (2015) 8:78 Page 7 of 8associated with a higher incidence of mixed chimerism.
Recipients of rabbit ATG were also observed to have a
higher incidence of viral and fungal infections [17].
Outside of the setting of a transplant, initial treatment
of SAA with horse ATG has shown to result in higher
responses rates than rabbit ATG [2]. However, rabbit
ATG is effective as salvage therapy for patients with
SAA who have disease that is refractory or has relapsed
after initial therapy with horse ATG [2, 18, 19]. These
findings suggest that differences in the pharmacokinetics
of these agents alone do not fully account for differences
in the biological activity of these agents in patients with
SAA. Recent data have shown that rabbit ATG depletes
different lymphocyte subsets compared to horse ATG,
and rabbit ATG is more likely to promote the expansion
of CD4 + CD25 bright FOXP3+ regulatory T cells [2, 20].
Taken altogether, these data establish rabbit and horse
ATG as having distinct in vitro and in vivo immunosup-
pressive properties that should be considered when
selecting the formulation of ATG to be utilized in the
transplant conditioning regimen.Conclusion
In this paired case report, we demonstrate the unique
experience of two monozygotic patients with bone mar-
row failure and MDS who received an allogeneic HPSC
transplant from the same donor, with the only difference
in the transplant regimen being the formulation of ATG
used in the preparative regimen. Remarkably, their T cell
engraftment profiles and clinical outcomes including
acute and chronic GVHD differed dramatically as a con-
sequence of this difference.
Rabbit ATG resulted in superior GVHD prophylaxis in
twin #1, which came at the cost of impeding donor T
cell engraftment placing the patient at risk for graft re-
jection. This case highlights that rabbit ATG and horse
ATG should not be considered interchangeable drugs,
with the need to consider these effects before choosing
the type of ATG to be used in the preparative regimen.
In the risk where graft rejection is low, one might con-
sider that rabbit ATG might be better suited to be uti-
lized as part of conditioning regimen, with salvage donor
lymphocyte infusions being incorporated into transplant
regimens to prevent graft rejection in patients with fall-
ing or low degrees of donor T cell chimerism. In situa-
tions where the risk of graft rejection or failure is high,
given its much shorter half-life, the use of horse ATG
may have a role in helping to eradicate recipient immun-
ity without leading to significant in vivo depletion of
donor T cells. In contrast, in scenarios where the risk of
GVHD may be high (i.e., HLA mismatched transplants),
the use of rabbit ATG in the preparative regimen may
be more appropriate and gives its greater ability to leadto in vivo donor T cell depletion which reduces the risk
of GVHD.
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